This functional ingredient is produced from barley extract through a proprietary triple-fermentation process involving Lactobacillus crispatus KT-11, yeast, and Aspergillus koji mold. Unlike single-organism fermentation common in the industry, this multi-stage process significantly increases the concentration of free amino acids — including a 93x increase in arginine and a 223x increase in proline compared to unfermented barley extract.
The fermentation yields high levels of dopamine precursors — phenylalanine, tyrosine, and tryptophan — which support the dopamine and serotonin-melatonin metabolic pathways. The final product is spray-dried into a fine, shelf-stable powder suitable for a wide range of supplement formats. No artificial additives or synthetic carriers are used in the manufacturing process.
Free from all 28 designated allergens under Japanese food labeling regulations, this ingredient offers a clean-label solution for formulators targeting the growing gut-brain axis, sleep support, and dopamine health categories.
This triple-fermented barley extract is rich in bioactive amino acids that serve as direct precursors to key neurotransmitters. Per 100 g, the ingredient contains 534 mg phenylalanine, 414 mg tyrosine, and 84 mg tryptophan — significantly higher than comparable plant-based sources such as garlic or peas.
Why it matters:
Phenylalanine and tyrosine are converted into L-DOPA and then dopamine — the neurotransmitter central to restless legs syndrome relief, motivation, and cognitive performance. Tryptophan is the precursor to serotonin and melatonin — supporting mood regulation and healthy sleep-wake cycles. The diverse metabolite profile from triple fermentation provides broad-spectrum prebiotic support, fueling the growth of beneficial gut bacteria more effectively than single-substrate prebiotics.
In vitro studies on PC12 adrenal cells demonstrated that this fermented barley extract stimulates dopamine production in a dose-dependent manner, achieving approximately 660% increase at 1000 μg/mL concentration compared to control. This effect positions the ingredient as a compelling option for brain health, focus, and sleep supplement lines.
Additionally, low-dose trials (82.5 mg/day for 2 weeks) showed a 75% increase in lactic acid bacteria and a 28% increase in Clostridium subcluster XIVa — a bacterial group associated with dopamine metabolism in the gut. This dual mechanism — direct dopamine precursor supply plus gut microbiome modulation — makes the ingredient uniquely relevant to the gut-brain axis trend.
Clinical trials and consumer studies have demonstrated the following benefits:
Gut microbiome improvement: Reduction in Bacteroides (opportunistic bacteria) in 4 out of 5 participants; increase in Lactobacillus (beneficial bacteria) in 3 out of 5 participants within 2 weeks at 330 mg/day.
Restless legs syndrome relief: Statistically significant reduction across all five RLS symptom criteria (unpleasant leg sensations, urge to move, impact on daily life, symptom frequency, overall severity) in a 4-week open-label trial with 10 female participants. Published in Ouyou Yakuri Vol. 88.
Stool quality improvement: Increased bowel movement frequency, reduced stool odor (80% of participants reported improvement), and decreased discomfort. Consumer satisfaction: 100% reported positive results.
Bifidobacterium growth: In vitro testing showed 10x bifidobacterium growth in 6 hours, compared to a decline with oligosaccharides under identical conditions.
Appearance: Fine yellowish-brown to brown powder (natural color variation).
Odor: Mild fermented aroma, characteristic of lactic acid fermented products.
Taste: Savory with slight umami notes — easily masked in capsule and tablet formats.
Solubility: Hygroscopic powder; consider moisture protection in formulation and storage.
Recommended daily intake: 90–330 mg/day for gut health, sleep support, and RLS relief. As low as 82.5 mg/day for microbiome modulation. The low effective dosage makes this ingredient highly economical in formulations — easily fitting into standard capsule and tablet formats.
Application forms: Tablets, capsules, granules, functional food products, and beverages. Due to its hygroscopic nature, encapsulation or moisture-barrier packaging is recommended. The powder blends well with other active ingredients and can serve as a multi-functional base for gut health, sleep, or brain health supplement lines.
We will help you choose the form, dosage, and packaging for your brand
The gut-brain axis is a bidirectional communication network connecting the gastrointestinal tract and the central nervous system. This connection operates through neural pathways (primarily the vagus nerve), immune signaling, and — critically — through metabolites produced by gut microbiota, including neurotransmitter precursors like dopamine and serotonin.
Research increasingly shows that the composition of gut bacteria directly influences brain function, mood, sleep quality, and neurological conditions. Approximately 95% of the body's serotonin and about 50% of its dopamine are produced in the gut, making intestinal health inseparable from mental and neurological well-being.
Dopamine is a neurotransmitter that plays a central role in motivation, reward processing, motor control, and sleep regulation. It is synthesized from the amino acids phenylalanine and tyrosine through a metabolic pathway that converts them into L-DOPA and then into dopamine.
Dopamine deficiency is linked to several conditions including restless legs syndrome, poor sleep quality, low motivation, and cognitive decline. While pharmaceutical dopamine agonists exist, there is growing demand for natural, food-based approaches to support healthy dopamine levels — particularly in the supplement and functional food industries.
Fermented foods and ingredients rich in dopamine precursors represent a promising category. Triple-fermented barley extract, with its concentrated amino acid profile and demonstrated ability to stimulate dopamine production in cell studies, addresses this demand with published scientific evidence.
Restless legs syndrome is a neurological condition characterized by uncomfortable sensations in the legs — often described as crawling, tingling, or burning — that worsen during periods of rest, particularly in the evening and at night. The condition significantly disrupts sleep and reduces quality of life.
RLS affects an estimated 5–10% of the adult population globally, with higher prevalence among women and older adults. In Japan alone, approximately 5 million people are affected. The condition is associated with dopaminergic dysfunction and iron deficiency, though the exact mechanisms remain under investigation.
Current treatments include dopamine agonists and iron supplementation, but side effects and long-term efficacy concerns drive interest in complementary nutritional approaches. A patented Japanese food ingredient has been clinically demonstrated to relieve RLS symptoms through its dopamine precursor content and direct stimulation of dopamine production — representing the first food-based solution with a patent specifically for RLS relief in Japan.
Fermentation has been used for centuries to enhance the nutritional profile of foods. In modern functional ingredient development, controlled fermentation dramatically increases the bioavailability and concentration of bioactive compounds. Lactic acid fermentation, in particular, produces metabolites that support gut health, immune function, and nutrient absorption.
Triple fermentation — using lactic acid bacteria, yeast, and koji mold simultaneously — is a more advanced approach that yields a broader spectrum of metabolites compared to single-organism processes. This diversity of metabolites provides more comprehensive prebiotic support, feeding a wider range of beneficial gut bacteria rather than selectively favoring only a few strains.
The Japanese fermentation tradition, rooted in centuries of koji and lactic acid culture, underpins many of today's most innovative functional ingredients. Products developed through these techniques combine traditional wisdom with modern clinical validation, meeting the global demand for evidence-based, natural health solutions.
【1】 A 4-week open-label trial with 10 female participants (ages 18–59) suffering from RLS and insomnia demonstrated significant improvement across all five RLS symptom criteria (VAS assessment) and improved bowel function including increased defecation frequency and reduced stool odor. Dosage: 323 mg/day in tablet form.
Publication: Ouyou Yakuri (Applied Pharmacology) Vol. 88, No. 5/6, pp. 69–74, 2015
【2】 In vitro study on PC12 adrenal cells showed dose-dependent stimulation of dopamine production, reaching approximately 660% increase at 1000 μg/mL. Comparable to dexamethasone positive control.
Publication: Ouyou Yakuri (Applied Pharmacology) Vol. 89, No. 1/2, pp. 5–8, 2015
【3】 Gut microbiome study: 5 adults, 330 mg/day for 2 weeks. Reduction in Bacteroides (4/5 participants), increase in Lactobacillus (3/5 participants). Low-dose study (82.5 mg/day) confirmed microbiome modulation with 75% lactic acid bacteria increase.
Publication: FOOD Style 21
【4】 Bifidobacterium proliferation test (in vitro): 1% solution showed 10x growth of bifidobacteria within 6 hours, while oligosaccharides under identical conditions showed a decline. Demonstrates superior prebiotic effect for rapid gut environment improvement.
【5】 Safety data: Acute toxicity test in rats (2,000 mg/kg body weight/day, single dose) and Ames mutagenicity test (5,000 μg/plate) — both confirmed safety with no adverse findings.
The recommended daily intake ranges from 90 to 330 mg for gut health improvement, sleep support, and RLS symptom relief. For microbiome modulation alone, doses as low as 82.5 mg/day have shown measurable results in clinical trials. The low effective dosage makes this ingredient highly economical for capsule and tablet formulations, requiring minimal space in multi-ingredient blends.
The triple-fermentation process concentrates dopamine precursor amino acids — phenylalanine (534 mg/100g) and tyrosine (414 mg/100g) — which are metabolized into L-DOPA and then dopamine. In vitro studies on PC12 cells demonstrated a 660% increase in dopamine production at therapeutic concentrations. Additionally, low-dose human trials showed increased levels of gut bacteria associated with dopamine metabolism, suggesting a dual mechanism through both direct precursor supply and microbiome modulation.
No. Although the fermentation process uses Lactobacillus crispatus KT-11, yeast, and koji mold, the product undergoes pasteurization at 110°C for 15 minutes during manufacturing. The final product is a postbiotic — containing beneficial metabolites, amino acids, and prebiotic compounds produced during fermentation, rather than live organisms. This makes it shelf-stable, easy to formulate, and suitable for heat-processed applications.
The powder integrates well into tablets, hard capsules, granules, functional food products, and beverages. Due to its hygroscopic nature, encapsulated formats with moisture-barrier packaging are recommended for optimal shelf life. The low effective dosage (from 82.5 mg/day) allows flexible formulation alongside other active ingredients for multi-benefit supplement lines targeting gut health, sleep, brain health, or dopamine support categories.
